F1_Rev.1_M3

C Number:	C20005
Lock Date:	10/10/2006
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	2.1.0

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF GINSENG

MALE MICE

Organ	Morphology
Adrenal Cortex	Hyperplasia
	Hypertrophy
Gallbladder	Inflammation
Heart: Artery	Inflammation
Intestine Small, Jejunum: Peyer's Patch	Hyperplasia
Kidney	Infarct
Liver	Clear Cell Focus
Lung: Alveolar Epithelium	Hyperplasia
Nose	Polyp, Inflammatory
Prostate	Inflammation
Spleen: Lymphoid Follicle	Atrophy
Testes	Mineralization

FEMALE MICE

Organ	Morphology
Adrenal Cortex	Hyperplasia
Bone: Femur	Fibro-osseous Lesion
Esophagus: Periesophageal Tissue	Inflammation
Heart	Cardiomyopathy
	Inflammation
Heart: Artery	Inflammation
Kidney	Infarct
	Inflammation
	Metaplasia Osseous
Liver	Eosinophilic Focus
	Tension Lipidosis
Liver: Hepatocyte	Necrosis
Lung	Congestion
Mammary Gland	Hyperplasia Focal
Pancreas	Infiltration Cellular
Pancreas: Acinus	Hyperplasia
Spleen	Hyperplasia Lymphoid

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF GINSENG

Uterus: Endometrium	Hyperplasia Cystic

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Adrenal Cortex Hyperplasia				
LESION RATES				
OVERALL (a)	10/50 (20%)	16/50 (32%)	16/50 (32%)	6/50 (12%)
POLY-3 RATE (b)	10/44.20	16/44.36	16/46.18	6/43.46
POLY-3 PERCENT (g)	22.6%	36.1%	34.7%	13.8%
TERMINAL (d)	8/32 (25%)	15/32 (47%)	16/38 (42%)	3/32 (9%)
FIRST INCIDENCE	673	689	730 (T)	560
STATISTICAL TESTS				
POLY 3	P=0.110N	P=0.121	P=0.150	P=0.214N
POLY 1.5	P=0.115N	P=0.123	P=0.141	P=0.217N
POLY 6	P=0.099N	P=0.117	P=0.160	P=0.205N
COCH-ARM / FISHERS	P=0.109N	P=0.127	P=0.127	P=0.207N
MAX-ISO-POLY-3	P=0.050N*	P=0.080	P=0.106	P=0.144N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Adrenal Cortex Hypertrophy				
LESION RATES				
OVERALL (a)	28/50 (56%)	24/50 (48%)	31/50 (62%)	35/50 (70%)
POLY-3 RATE (b)	28/45.80	24/44.89	31/47.34	35/44.64
POLY-3 PERCENT (g)	61.1%	53.5%	65.5%	78.4%
TERMINAL (d)	21/32 (66%)	20/32 (63%)	26/38 (68%)	28/32 (88%)
FIRST INCIDENCE	562	641	632	560
STATISTICAL TESTS				
POLY 3	P=0.017*	P=0.295N	P=0.411	P=0.050*
POLY 1.5	P=0.020*	P=0.286N	P=0.385	P=0.060
POLY 6	P=0.016*	P=0.314N	P=0.448	P=0.043*
COCH-ARM / FISHERS	P=0.036*	P=0.274N	P=0.342	P=0.107
MAX-ISO-POLY-3	P=0.023*	P=0.227N	P=0.330	P=0.031*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Adrenal Medulla				
Hyperplasia				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/43.94	0/44.20	1/46.18	0/42.27
POLY-3 PERCENT (g)	4.6%	0%	2.2%	0%
TERMINAL (d)	1/32 (3%)	0/32 (0%)	1/38 (3%)	0/32 (0%)
FIRST INCIDENCE	708	---	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.191N	P=0.236N	P=0.483N	P=0.246N
POLY 1.5	P=0.191N	P=0.237N	P=0.489N	P=0.244N
POLY 6	P=0.190N	P=0.235N	P=0.474N	P=0.246N
COCH-ARM / FISHERS	P=0.188N	P=0.247N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.088N	P=0.076N	P=0.271N	P=0.084N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Bone Marrow Hyperplasia				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.93	0/44.20	1/46.75	0/42.27
POLY-3 PERCENT (g)	2.3%	0%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	710	---	554	---
STATISTICAL TESTS				
POLY 3	P=0.410N	P=0.499N	P=0.747N	P=0.508N
POLY 1.5	P=0.410N	P=0.499N	P=0.752N	P=0.506N
POLY 6	P=0.410N	P=0.498N	P=0.740N	P=0.508N
COCH-ARM / FISHERS	P=0.405N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.270N	P=0.158N	P=0.482N	P=0.168N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Bone: Femur				
Fibro-osseous Lesion				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Brain				
Hydrocephalus				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Epididymis				
Granuloma Sperm				
LESION RATES				
OVERALL (a)	2/50 (4%)	4/50 (8%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/44.19	4/44.54	1/46.18	1/42.27
POLY-3 PERCENT (g)	4.5%	9%	2.2%	2.4%
TERMINAL (d)	1/32 (3%)	3/32 (9%)	1/38 (3%)	1/32 (3%)
FIRST INCIDENCE	637	633	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.241N	P=0.341	P=0.485N	P=0.515N
POLY 1.5	P=0.240N	P=0.339	P=0.490N	P=0.512N
POLY 6	P=0.240N	P=0.342	P=0.477N	P=0.517N
COCH-ARM / FISHERS	P=0.232N	P=0.339	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.266N	P=0.204	P=0.272N	P=0.297N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Epididymis				
Inflammation				
LESION RATES				
OVERALL (a)	2/50 (4%)	4/50 (8%)	6/50 (12%)	2/50 (4%)
POLY-3 RATE (b)	2/43.85	4/44.62	6/46.18	2/42.57
POLY-3 PERCENT (g)	4.6%	9%	13%	4.7%
TERMINAL (d)	2/32 (6%)	3/32 (9%)	6/38 (16%)	1/32 (3%)
FIRST INCIDENCE	730 (T)	609	730 (T)	651
STATISTICAL TESTS				
POLY 3	P=0.561N	P=0.345	P=0.150	P=0.683
POLY 1.5	P=0.559N	P=0.341	P=0.144	P=0.684
POLY 6	P=0.558N	P=0.350	P=0.159	P=0.686
COCH-ARM / FISHERS	P=0.537N	P=0.339	P=0.134	P=0.691N
MAX-ISO-POLY-3	P=0.368	P=0.208	P=0.085	P=0.487

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Esophagus				
Perforation				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Esophagus: Periesophageal Tissue Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	1/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	2.2%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	1/38 (3%)	0/32 (0%)
FIRST INCIDENCE	---	---	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.673	(e)	P=0.510	(e)
POLY 1.5	P=0.678	(e)	P=0.506	(e)
POLY 6	P=0.671	(e)	P=0.516	(e)
COCH-ARM / FISHERS	P=0.694	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.402	(e)	P=0.172	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Eye: Cornea				
Inflammation				
LESION RATES				
OVERALL (a)	3/50 (6%)	3/50 (6%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	3/44.32	3/45.11	1/46.89	3/43.94
POLY-3 PERCENT (g)	6.8%	6.7%	2.1%	6.8%
TERMINAL (d)	1/32 (3%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	637	562	486	483
STATISTICAL TESTS				
POLY 3	P=0.543N	P=0.654N	P=0.285N	P=0.659
POLY 1.5	P=0.545N	P=0.658N	P=0.293N	P=0.656
POLY 6	P=0.538N	P=0.650N	P=0.277N	P=0.662N
COCH-ARM / FISHERS	P=0.544N	P=0.661N	P=0.309N	P=0.661N
MAX-ISO-POLY-3	P=0.505N	P=0.490N	P=0.147N	P=0.495

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Gallbladder				
Cyst				
LESION RATES				
OVERALL (a)	1/49 (2%)	0/50 (0%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.54	0/44.20	1/45.18	0/42.27
POLY-3 PERCENT (g)	2.3%	0%	2.2%	0%
TERMINAL (d)	1/32 (3%)	0/32 (0%)	1/37 (3%)	0/32 (0%)
FIRST INCIDENCE	730 (T)	---	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.409N	P=0.497N	P=0.752N	P=0.506N
POLY 1.5	P=0.407N	P=0.497N	P=0.756N	P=0.504N
POLY 6	P=0.408N	P=0.497N	P=0.748N	P=0.507N
COCH-ARM / FISHERS	P=0.402N	P=0.495N	P=0.753N	P=0.495N
MAX-ISO-POLY-3	P=0.269N	P=0.157N	P=0.489N	P=0.167N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Gallbladder Inflammation				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/50 (0%)	0/49 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.54	0/44.20	0/45.18	2/42.27
POLY-3 PERCENT (g)	0%	0%	0%	4.7%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/37 (0%)	2/32 (6%)
FIRST INCIDENCE	---	---	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.045*	(e)	(e)	P=0.230
POLY 1.5	P=0.045*	(e)	(e)	P=0.233
POLY 6	P=0.045*	(e)	(e)	P=0.229
COCH-ARM / FISHERS	P=0.047*	(e)	(e)	P=0.253
MAX-ISO-POLY-3	P=0.033*	(e)	(e)	P=0.077

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Harderian Gland				
Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/43.85	2/44.20	1/46.18	1/42.27
POLY-3 PERCENT (g)	0%	4.5%	2.2%	2.4%
TERMINAL (d)	0/32 (0%)	2/32 (6%)	1/38 (3%)	1/32 (3%)
FIRST INCIDENCE	---	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.484	P=0.239	P=0.510	P=0.493
POLY 1.5	P=0.487	P=0.238	P=0.506	P=0.494
POLY 6	P=0.485	P=0.239	P=0.516	P=0.493
COCH-ARM / FISHERS	P=0.500	P=0.247	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.293	P=0.077	P=0.172	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Heart				
Cardiomyopathy				
LESION RATES				
OVERALL (a)	42/50 (84%)	43/50 (86%)	45/50 (90%)	41/50 (82%)
POLY-3 RATE (b)	42/47.32	43/46.93	45/48.15	41/45.89
POLY-3 PERCENT (g)	88.8%	91.6%	93.5%	89.4%
TERMINAL (d)	30/32 (94%)	30/32 (94%)	38/38 (100%)	30/32 (94%)
FIRST INCIDENCE	562	562	554	417
STATISTICAL TESTS				
POLY 3	P=0.552	P=0.447	P=0.309	P=0.604
POLY 1.5	P=0.556N	P=0.463	P=0.304	P=0.623
POLY 6	P=0.509	P=0.435	P=0.302	P=0.573
COCH-ARM / FISHERS	P=0.433N	P=0.500	P=0.277	P=0.500N
MAX-ISO-POLY-3	P=0.489	P=0.303	P=0.186	P=0.459

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Heart				
Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	2/45.21	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	4.4%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	269	---	---
STATISTICAL TESTS				
POLY 3	P=0.402N	P=0.244	(e)	(e)
POLY 1.5	P=0.404N	P=0.242	(e)	(e)
POLY 6	P=0.398N	P=0.246	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.272N	P=0.082	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Heart **Mineralization**				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/44.37	0/44.20	1/46.38	0/42.27
POLY-3 PERCENT (g)	2.3%	0%	2.2%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	571	---	679	---
STATISTICAL TESTS				
POLY 3	P=0.411N	P=0.501N	P=0.751N	P=0.510N
POLY 1.5	P=0.410N	P=0.501N	P=0.754N	P=0.507N
POLY 6	P=0.411N	P=0.501N	P=0.746N	P=0.511N
COCH-ARM / FISHERS	P=0.405N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.274N	P=0.159N	P=0.487N	P=0.171N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Heart: Artery				
Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	3/45.58	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	6.6%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	269	---	---
STATISTICAL TESTS				
POLY 3	P=0.307N	P=0.126	(e)	(e)
POLY 1.5	P=0.309N	P=0.123	(e)	(e)
POLY 6	P=0.302N	P=0.128	(e)	(e)
COCH-ARM / FISHERS	P=0.311N	P=0.121	(e)	(e)
MAX-ISO-POLY-3	P=0.188N	P=0.044*	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Heart: Valve				
Thrombosis				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Intestine Small, Jejunum: Peyer's Patch Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	2/42.27
POLY-3 PERCENT (g)	0%	0%	0%	4.7%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	2/32 (6%)
FIRST INCIDENCE	---	---	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.044*	(e)	(e)	P=0.229
POLY 1.5	P=0.044*	(e)	(e)	P=0.230
POLY 6	P=0.044*	(e)	(e)	P=0.229
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.032*	(e)	(e)	P=0.076

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Islets, Pancreatic **Hyperplasia**				
LESION RATES				
OVERALL (a)	38/50 (76%)	38/50 (76%)	38/50 (76%)	40/50 (80%)
POLY-3 RATE (b)	38/47.76	38/48.63	38/48.65	40/47.58
POLY-3 PERCENT (g)	79.6%	78.1%	78.1%	84.1%
TERMINAL (d)	27/32 (84%)	26/32 (81%)	30/38 (79%)	29/32 (91%)
FIRST INCIDENCE	339	269	486	417
STATISTICAL TESTS				
POLY 3	P=0.300	P=0.532N	P=0.531N	P=0.375
POLY 1.5	P=0.289	P=0.558N	P=0.560N	P=0.355
POLY 6	P=0.318	P=0.500N	P=0.481N	P=0.403
COCH-ARM / FISHERS	P=0.345	P=0.592N	P=0.592N	P=0.405
MAX-ISO-POLY-3	P=0.399	P=0.429N	P=0.427N	P=0.277

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Cyst				
LESION RATES				
OVERALL (a)	9/50 (18%)	6/50 (12%)	7/50 (14%)	7/50 (14%)
POLY-3 RATE (b)	9/44.69	6/44.64	7/47.46	7/43.47
POLY-3 PERCENT (g)	20.1%	13.4%	14.8%	16.1%
TERMINAL (d)	7/32 (22%)	4/32 (13%)	5/38 (13%)	4/32 (13%)
FIRST INCIDENCE	578	668	486	558
STATISTICAL TESTS				
POLY 3	P=0.419N	P=0.287N	P=0.342N	P=0.415N
POLY 1.5	P=0.421N	P=0.288N	P=0.361N	P=0.414N
POLY 6	P=0.412N	P=0.285N	P=0.321N	P=0.410N
COCH-ARM / FISHERS	P=0.406N	P=0.288N	P=0.393N	P=0.393N
MAX-ISO-POLY-3	P=0.406N	P=0.199N	P=0.255N	P=0.314N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Hydronephrosis				
LESION RATES				
OVERALL (a)	2/50 (4%)	2/50 (4%)	3/50 (6%)	3/50 (6%)
POLY-3 RATE (b)	2/43.99	2/44.41	3/46.18	3/42.27
POLY-3 PERCENT (g)	4.6%	4.5%	6.5%	7.1%
TERMINAL (d)	1/32 (3%)	1/32 (3%)	3/38 (8%)	3/32 (9%)
FIRST INCIDENCE	695	675	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.351	P=0.691N	P=0.522	P=0.482
POLY 1.5	P=0.355	P=0.692N	P=0.514	P=0.485
POLY 6	P=0.349	P=0.689N	P=0.533	P=0.480
COCH-ARM / FISHERS	P=0.371	P=0.691N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.494	P=0.495N	P=0.347	P=0.311

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Infarct				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	1/43.85	0/44.20	1/46.18	4/42.32
POLY-3 PERCENT (g)	2.3%	0%	2.2%	9.5%
TERMINAL (d)	1/32 (3%)	0/32 (0%)	1/38 (3%)	3/32 (9%)
FIRST INCIDENCE	730 (T)	---	730 (T)	718
STATISTICAL TESTS				
POLY 3	P=0.031*	P=0.498N	P=0.749N	P=0.167
POLY 1.5	P=0.032*	P=0.499N	P=0.753N	P=0.169
POLY 6	P=0.031*	P=0.498N	P=0.743N	P=0.167
COCH-ARM / FISHERS	P=0.034*	P=0.500N	P=0.753N	P=0.181
MAX-ISO-POLY-3	P=0.028*	P=0.158N	P=0.485N	P=0.080

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Inflammation				
LESION RATES				
OVERALL (a)	2/50 (4%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/43.85	2/44.43	1/46.18	1/42.32
POLY-3 PERCENT (g)	4.6%	4.5%	2.2%	2.4%
TERMINAL (d)	2/32 (6%)	1/32 (3%)	1/38 (3%)	0/32 (0%)
FIRST INCIDENCE	730 (T)	668	730 (T)	718
STATISTICAL TESTS				
POLY 3	P=0.344N	P=0.689N	P=0.482N	P=0.512N
POLY 1.5	P=0.344N	P=0.692N	P=0.489N	P=0.511N
POLY 6	P=0.342N	P=0.686N	P=0.473N	P=0.512N
COCH-ARM / FISHERS	P=0.337N	P=0.691N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.457N	P=0.494N	P=0.270N	P=0.294N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Metaplasia Osseous				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	2/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	4.3%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	2/38 (5%)	0/32 (0%)
FIRST INCIDENCE	---	---	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.569	(e)	P=0.249	(e)
POLY 1.5	P=0.574	(e)	P=0.244	(e)
POLY 6	P=0.566	(e)	P=0.255	(e)
COCH-ARM / FISHERS	P=0.595	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.269	(e)	P=0.087	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney **Mineralization**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	2/46.72	0/42.27
POLY-3 PERCENT (g)	0%	0%	4.3%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	637	---
STATISTICAL TESTS				
POLY 3	P=0.568	(e)	P=0.252	(e)
POLY 1.5	P=0.574	(e)	P=0.246	(e)
POLY 6	P=0.564	(e)	P=0.260	(e)
COCH-ARM / FISHERS	P=0.595	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.271	(e)	P=0.090	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Nephropathy				
LESION RATES				
OVERALL (a)	48/50 (96%)	47/50 (94%)	48/50 (96%)	47/50 (94%)
POLY-3 RATE (b)	48/49.02	47/47.91	48/49.44	47/48.19
POLY-3 PERCENT (g)	97.9%	98.1%	97.1%	97.5%
TERMINAL (d)	32/32 (100%)	32/32 (100%)	37/38 (97%)	31/32 (97%)
FIRST INCIDENCE	492	542	486	429
STATISTICAL TESTS				
POLY 3	P=0.559N	P=0.793	P=0.661N	P=0.723N
POLY 1.5	P=0.586N	P=0.698N	P=0.656N	P=0.709N
POLY 6	P=0.522N	P=0.726	P=0.694N	P=0.730N
COCH-ARM / FISHERS	P=0.456N	P=0.500N	P=0.691N	P=0.500N
MAX-ISO-POLY-3	P=0.622N	P=0.467	P=0.387N	P=0.445N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney: Artery **Inflammation**				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	2/44.43	1/46.25	0/42.27
POLY-3 PERCENT (g)	0%	4.5%	2.2%	0%
TERMINAL (d)	0/32 (0%)	1/32 (3%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	668	714	---
STATISTICAL TESTS				
POLY 3	P=0.469N	P=0.240	P=0.511	(e)
POLY 1.5	P=0.469N	P=0.239	P=0.506	(e)
POLY 6	P=0.467N	P=0.242	P=0.516	(e)
COCH-ARM / FISHERS	P=0.461N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.348N	P=0.079	P=0.172	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney: Renal Tubule Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	2/44.20	2/46.18	0/42.27
POLY-3 PERCENT (g)	0%	4.5%	4.3%	0%
TERMINAL (d)	0/32 (0%)	2/32 (6%)	2/38 (5%)	0/32 (0%)
FIRST INCIDENCE	---	730 (T)	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.516N	P=0.239	P=0.249	(e)
POLY 1.5	P=0.513N	P=0.238	P=0.244	(e)
POLY 6	P=0.515N	P=0.239	P=0.255	(e)
COCH-ARM / FISHERS	P=0.500N	P=0.247	P=0.247	(e)
MAX-ISO-POLY-3	P=0.292	P=0.077	P=0.087	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Angiectasis				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.85	1/44.40	0/46.18	0/42.27
POLY-3 PERCENT (g)	2.3%	2.3%	0%	0%
TERMINAL (d)	1/32 (3%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	730 (T)	676	---	---
STATISTICAL TESTS				
POLY 3	P=0.234N	P=0.758N	P=0.490N	P=0.507N
POLY 1.5	P=0.236N	P=0.759N	P=0.494N	P=0.506N
POLY 6	P=0.233N	P=0.756N	P=0.484N	P=0.507N
COCH-ARM / FISHERS	P=0.236N	P=0.753N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.270N	P=0.496N	P=0.158N	P=0.168N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Basophilic Focus				
LESION RATES				
OVERALL (a)	3/50 (6%)	3/50 (6%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	3/44.79	3/44.52	4/46.18	1/42.27
POLY-3 PERCENT (g)	6.7%	6.7%	8.7%	2.4%
TERMINAL (d)	1/32 (3%)	2/32 (6%)	4/38 (11%)	1/32 (3%)
FIRST INCIDENCE	562	641	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.273N	P=0.660	P=0.517	P=0.326N
POLY 1.5	P=0.267N	P=0.660	P=0.511	P=0.321N
POLY 6	P=0.278N	P=0.659	P=0.524	P=0.331N
COCH-ARM / FISHERS	P=0.248N	P=0.661N	P=0.500	P=0.309N
MAX-ISO-POLY-3	P=0.284N	P=0.496	P=0.365	P=0.175N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Clear Cell Focus				
LESION RATES				
OVERALL (a)	11/50 (22%)	21/50 (42%)	21/50 (42%)	16/50 (32%)
POLY-3 RATE (b)	11/44.20	21/44.73	21/46.38	16/42.27
POLY-3 PERCENT (g)	24.9%	47%	45.3%	37.9%
TERMINAL (d)	9/32 (28%)	19/32 (59%)	20/38 (53%)	16/32 (50%)
FIRST INCIDENCE	673	641	678	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.223	P=0.022*	P=0.032*	P=0.139
POLY 1.5	P=0.240	P=0.023*	P=0.029*	P=0.150
POLY 6	P=0.209	P=0.021*	P=0.036*	P=0.130
COCH-ARM / FISHERS	P=0.299	P=0.026*	P=0.026*	P=0.184
MAX-ISO-POLY-3	P=0.061	P=0.013*	P=0.021*	P=0.098

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Eosinophilic Focus				
LESION RATES				
OVERALL (a)	17/50 (34%)	16/50 (32%)	18/50 (36%)	21/50 (42%)
POLY-3 RATE (b)	17/44.05	16/45.62	18/47.11	21/42.89
POLY-3 PERCENT (g)	38.6%	35.1%	38.2%	49%
TERMINAL (d)	15/32 (47%)	11/32 (34%)	16/38 (42%)	16/32 (50%)
FIRST INCIDENCE	696	609	549	617
STATISTICAL TESTS				
POLY 3	P=0.144	P=0.449N	P=0.571N	P=0.220
POLY 1.5	P=0.152	P=0.474N	P=0.560	P=0.227
POLY 6	P=0.142	P=0.413N	P=0.521N	P=0.223
COCH-ARM / FISHERS	P=0.185	P=0.500N	P=0.500	P=0.268
MAX-ISO-POLY-3	P=0.205	P=0.365N	P=0.485N	P=0.164

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver Inflammation				
LESION RATES				
OVERALL (a)	8/50 (16%)	4/50 (8%)	7/50 (14%)	3/50 (6%)
POLY-3 RATE (b)	8/44.90	4/44.20	7/46.53	3/42.27
POLY-3 PERCENT (g)	17.8%	9.1%	15%	7.1%
TERMINAL (d)	5/32 (16%)	4/32 (13%)	6/38 (16%)	3/32 (9%)
FIRST INCIDENCE	571	730 (T)	632	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.144N	P=0.183N	P=0.470N	P=0.117N
POLY 1.5	P=0.140N	P=0.181N	P=0.481N	P=0.112N
POLY 6	P=0.146N	P=0.188N	P=0.457N	P=0.122N
COCH-ARM / FISHERS	P=0.126N	P=0.178N	P=0.500N	P=0.100N
MAX-ISO-POLY-3	P=0.112N	P=0.114N	P=0.362N	P=0.070N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Mixed Cell Focus				
LESION RATES				
OVERALL (a)	8/50 (16%)	6/50 (12%)	5/50 (10%)	5/50 (10%)
POLY-3 RATE (b)	8/44.42	6/44.68	5/46.49	5/42.71
POLY-3 PERCENT (g)	18%	13.4%	10.8%	11.7%
TERMINAL (d)	6/32 (19%)	4/32 (13%)	4/38 (11%)	3/32 (9%)
FIRST INCIDENCE	578	609	646	651
STATISTICAL TESTS				
POLY 3	P=0.247N	P=0.381N	P=0.246N	P=0.300N
POLY 1.5	P=0.246N	P=0.385N	P=0.258N	P=0.297N
POLY 6	P=0.243N	P=0.377N	P=0.231N	P=0.299N
COCH-ARM / FISHERS	P=0.231N	P=0.387N	P=0.277N	P=0.277N
MAX-ISO-POLY-3	P=0.297N	P=0.278N	P=0.168N	P=0.210N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Tension Lipidosis				
LESION RATES				
OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	2/43.98	3/44.61	3/46.38	1/42.27
POLY-3 PERCENT (g)	4.6%	6.7%	6.5%	2.4%
TERMINAL (d)	1/32 (3%)	1/32 (3%)	2/38 (5%)	1/32 (3%)
FIRST INCIDENCE	696	675	678	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.361N	P=0.506	P=0.524	P=0.514N
POLY 1.5	P=0.359N	P=0.503	P=0.515	P=0.511N
POLY 6	P=0.362N	P=0.511	P=0.537	P=0.515N
COCH-ARM / FISHERS	P=0.343N	P=0.500	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.379N	P=0.330	P=0.349	P=0.296N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver: Hepatocyte Necrosis				
LESION RATES				
OVERALL (a)	3/50 (6%)	4/50 (8%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	3/44.37	4/45.06	4/47.39	1/42.27
POLY-3 PERCENT (g)	6.8%	8.9%	8.4%	2.4%
TERMINAL (d)	2/32 (6%)	1/32 (3%)	1/38 (3%)	1/32 (3%)
FIRST INCIDENCE	571	609	554	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.231N	P=0.508	P=0.536	P=0.323N
POLY 1.5	P=0.227N	P=0.504	P=0.521	P=0.319N
POLY 6	P=0.233N	P=0.515	P=0.555	P=0.325N
COCH-ARM / FISHERS	P=0.210N	P=0.500	P=0.500	P=0.309N
MAX-ISO-POLY-3	P=0.252N	P=0.356	P=0.384	P=0.172N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver: Hepatocyte				
Vacuolization Cytoplasmic Diffuse				
LESION RATES				
OVERALL (a)	12/50 (24%)	15/50 (30%)	11/50 (22%)	17/50 (34%)
POLY-3 RATE (b)	12/46.04	15/46.95	11/46.73	17/45.14
POLY-3 PERCENT (g)	26.1%	32%	23.5%	37.7%
TERMINAL (d)	6/32 (19%)	6/32 (19%)	9/38 (24%)	11/32 (34%)
FIRST INCIDENCE	339	539	632	483
STATISTICAL TESTS				
POLY 3	P=0.179	P=0.346	P=0.484N	P=0.166
POLY 1.5	P=0.180	P=0.333	P=0.491N	P=0.165
POLY 6	P=0.183	P=0.369	P=0.471N	P=0.174
COCH-ARM / FISHERS	P=0.203	P=0.326	P=0.500N	P=0.189
MAX-ISO-POLY-3	P=0.184	P=0.268	P=0.388N	P=0.118

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung				
Congestion				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung				
Hemorrhage				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.85	0/44.20	2/46.38	0/42.27
POLY-3 PERCENT (g)	2.3%	0%	4.3%	0%
TERMINAL (d)	1/32 (3%)	0/32 (0%)	1/38 (3%)	0/32 (0%)
FIRST INCIDENCE	730 (T)	---	679	---
STATISTICAL TESTS				
POLY 3	P=0.474N	P=0.498N	P=0.520	P=0.507N
POLY 1.5	P=0.472N	P=0.499N	P=0.512	P=0.506N
POLY 6	P=0.475N	P=0.498N	P=0.530	P=0.507N
COCH-ARM / FISHERS	P=0.461N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.346N	P=0.158N	P=0.302	P=0.168N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung				
Inflammation				
LESION RATES				
OVERALL (a)	4/50 (8%)	2/50 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	4/44.39	2/44.21	2/46.18	1/42.27
POLY-3 PERCENT (g)	9%	4.5%	4.3%	2.4%
TERMINAL (d)	3/32 (9%)	1/32 (3%)	2/38 (5%)	1/32 (3%)
FIRST INCIDENCE	562	728	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.144N	P=0.339N	P=0.319N	P=0.193N
POLY 1.5	P=0.143N	P=0.339N	P=0.326N	P=0.190N
POLY 6	P=0.144N	P=0.339N	P=0.310N	P=0.195N
COCH-ARM / FISHERS	P=0.137N	P=0.339N	P=0.339N	P=0.181N
MAX-ISO-POLY-3	P=0.138N	P=0.202N	P=0.191N	P=0.098N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung				
Thrombosis				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/44.37	0/44.20	2/46.73	1/42.27
POLY-3 PERCENT (g)	2.3%	0%	4.3%	2.4%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	1/32 (3%)
FIRST INCIDENCE	571	---	632	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.478	P=0.501N	P=0.518	P=0.750
POLY 1.5	P=0.483	P=0.501N	P=0.511	P=0.752
POLY 6	P=0.475	P=0.501N	P=0.528	P=0.749
COCH-ARM / FISHERS	P=0.500	P=0.500N	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.403	P=0.159N	P=0.300	P=0.486

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung: Alveolar Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	3/50 (6%)	1/50 (2%)	6/50 (12%)	0/50 (0%)
POLY-3 RATE (b)	3/44.07	1/44.36	6/46.49	0/42.27
POLY-3 PERCENT (g)	6.8%	2.3%	12.9%	0%
TERMINAL (d)	2/32 (6%)	0/32 (0%)	5/38 (13%)	0/32 (0%)
FIRST INCIDENCE	673	689	646	---
STATISTICAL TESTS				
POLY 3	P=0.242N	P=0.303N	P=0.269	P=0.126N
POLY 1.5	P=0.237N	P=0.304N	P=0.259	P=0.125N
POLY 6	P=0.245N	P=0.301N	P=0.283	P=0.126N
COCH-ARM / FISHERS	P=0.221N	P=0.309N	P=0.243	P=0.121N
MAX-ISO-POLY-3	P=0.112N	P=0.153N	P=0.174	P=0.044N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung: Alveolus				
Infiltration Cellular Histiocyte				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	1/42.27
POLY-3 PERCENT (g)	0%	0%	0%	2.4%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	1/32 (3%)
FIRST INCIDENCE	---	---	---	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.194	(e)	(e)	P=0.493
POLY 1.5	P=0.195	(e)	(e)	P=0.494
POLY 6	P=0.194	(e)	(e)	P=0.493
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.123	(e)	(e)	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lymph Node, Mandibular				
Infiltration Cellular Histiocyte				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lymph Node, Mesenteric				
Infiltration Cellular Histiocyte				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/43.62	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lymph Node, Mesenteric				
Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/43.62	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lymph Node: Renal				
Hemorrhage				
LESION RATES				
OVERALL (a)	0/2 (0%)	0/2 (0%)	0/2 (0%)	0/1 (0%)
POLY-3 RATE (b)	0/1.68	0/1.79	0/1.13	0/1.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Mammary Gland				
Hyperplasia Focal				
LESION RATES				
OVERALL (a)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.66	0/0.00	0/0.66	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Mesentery				
Necrosis				
LESION RATES				
OVERALL (a)	2/3 (67%)	2/4 (50%)	4/6 (67%)	0/0 (0%)
POLY-3 RATE (b)	2/3.00	2/3.79	4/5.36	0/0.00
POLY-3 PERCENT (g)	66.7%	52.7%	74.7%	0%
TERMINAL (d)	1/2 (50%)	1/2 (50%)	4/4 (100%)	0/0 (0%)
FIRST INCIDENCE	578	542	730 (T)	---
STATISTICAL TESTS				
POLY 3	(e)	P=0.642N	P=0.704	(e)
POLY 1.5	(e)	P=0.627N	P=0.726	(e)
POLY 6	(e)	P=0.668N	P=0.655	(e)
COCH-ARM / FISHERS	P=0.727	P=0.629N	P=0.762	(e)
MAX-ISO-POLY-3	(e)	P=0.378N	P=0.413	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Nose				
Inflammation				
LESION RATES				
OVERALL (a)	6/50 (12%)	5/49 (10%)	7/49 (14%)	6/50 (12%)
POLY-3 RATE (b)	6/44.53	5/44.25	7/46.04	6/43.62
POLY-3 PERCENT (g)	13.5%	11.3%	15.2%	13.8%
TERMINAL (d)	4/32 (13%)	2/32 (6%)	4/38 (11%)	3/32 (9%)
FIRST INCIDENCE	562	668	549	417
STATISTICAL TESTS				
POLY 3	P=0.486	P=0.504N	P=0.526	P=0.607
POLY 1.5	P=0.487	P=0.509N	P=0.510	P=0.607
POLY 6	P=0.488	P=0.498N	P=0.547	P=0.609
COCH-ARM / FISHERS	P=0.504	P=0.514N	P=0.484	P=0.620N
MAX-ISO-POLY-3	P=0.608	P=0.377N	P=0.408	P=0.484

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Nose				
Polyp, Inflammatory				
LESION RATES				
OVERALL (a)	0/50 (0%)	3/49 (6%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	3/44.03	0/45.20	0/42.27
POLY-3 PERCENT (g)	0%	6.8%	0%	0%
TERMINAL (d)	0/32 (0%)	2/32 (6%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	668	---	---
STATISTICAL TESTS				
POLY 3	P=0.309N	P=0.119	(e)	(e)
POLY 1.5	P=0.311N	P=0.117	(e)	(e)
POLY 6	P=0.304N	P=0.121	(e)	(e)
COCH-ARM / FISHERS	P=0.311N	P=0.117	(e)	(e)
MAX-ISO-POLY-3	P=0.183N	P=0.039*	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pancreas				
Basophilic Focus				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.85	1/44.20	1/46.18	0/42.27
POLY-3 PERCENT (g)	2.3%	2.3%	2.2%	0%
TERMINAL (d)	1/32 (3%)	1/32 (3%)	1/38 (3%)	0/32 (0%)
FIRST INCIDENCE	730 (T)	730 (T)	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.319N	P=0.759N	P=0.749N	P=0.507N
POLY 1.5	P=0.318N	P=0.760N	P=0.753N	P=0.506N
POLY 6	P=0.317N	P=0.758N	P=0.743N	P=0.507N
COCH-ARM / FISHERS	P=0.311N	P=0.753N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.348N	P=0.497N	P=0.485N	P=0.168N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pancreas				
Infiltration Cellular				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.85	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	1/32 (3%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	730 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.299N	P=0.498N	P=0.490N	P=0.507N
POLY 1.5	P=0.301N	P=0.499N	P=0.494N	P=0.506N
POLY 6	P=0.298N	P=0.498N	P=0.484N	P=0.507N
COCH-ARM / FISHERS	P=0.306N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.136N	P=0.158N	P=0.158N	P=0.168N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pancreas				
Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pancreas: Acinus **Hyperplasia**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pituitary Gland: Pars Distalis				
Cyst				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	5/50 (10%)
POLY-3 RATE (b)	2/44.13	1/44.20	1/46.18	5/42.27
POLY-3 PERCENT (g)	4.5%	2.3%	2.2%	11.8%
TERMINAL (d)	1/32 (3%)	1/32 (3%)	1/38 (3%)	5/32 (16%)
FIRST INCIDENCE	653	730 (T)	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.070	P=0.500N	P=0.484N	P=0.198
POLY 1.5	P=0.070	P=0.500N	P=0.490N	P=0.202
POLY 6	P=0.070	P=0.500N	P=0.477N	P=0.195
COCH-ARM / FISHERS	P=0.075	P=0.500N	P=0.500N	P=0.218
MAX-ISO-POLY-3	P=0.053	P=0.280N	P=0.272N	P=0.111

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pituitary Gland: Pars Distalis				
Hyperplasia				
LESION RATES				
OVERALL (a)	3/50 (6%)	4/50 (8%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	3/43.98	4/44.28	2/46.18	3/43.27
POLY-3 PERCENT (g)	6.8%	9%	4.3%	6.9%
TERMINAL (d)	2/32 (6%)	3/32 (9%)	2/38 (5%)	2/32 (6%)
FIRST INCIDENCE	696	708	730 (T)	18
STATISTICAL TESTS				
POLY 3	P=0.503N	P=0.504	P=0.478N	P=0.655
POLY 1.5	P=0.502N	P=0.502	P=0.486N	P=0.658
POLY 6	P=0.501N	P=0.506	P=0.467N	P=0.655
COCH-ARM / FISHERS	P=0.500N	P=0.500	P=0.500N	P=0.661N
MAX-ISO-POLY-3	P=0.532N	P=0.350	P=0.308N	P=0.491

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Preputial Gland Inflammation				
LESION RATES				
OVERALL (a)	5/50 (10%)	6/50 (12%)	4/50 (8%)	8/50 (16%)
POLY-3 RATE (b)	5/44.25	6/44.52	4/46.18	8/42.27
POLY-3 PERCENT (g)	11.3%	13.5%	8.7%	18.9%
TERMINAL (d)	4/32 (13%)	4/32 (13%)	4/38 (11%)	8/32 (25%)
FIRST INCIDENCE	617	676	730 (T)	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.216	P=0.504	P=0.473N	P=0.245
POLY 1.5	P=0.221	P=0.502	P=0.483N	P=0.252
POLY 6	P=0.213	P=0.508	P=0.461N	P=0.239
COCH-ARM / FISHERS	P=0.238	P=0.500	P=0.500N	P=0.277
MAX-ISO-POLY-3	P=0.239	P=0.377	P=0.341N	P=0.166

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Preputial Gland: Duct Ectasia				
LESION RATES				
OVERALL (a)	9/50 (18%)	7/50 (14%)	6/50 (12%)	12/50 (24%)
POLY-3 RATE (b)	9/44.15	7/46.30	6/46.20	12/42.92
POLY-3 PERCENT (g)	20.4%	15.1%	13%	28%
TERMINAL (d)	7/32 (22%)	2/32 (6%)	5/38 (13%)	10/32 (31%)
FIRST INCIDENCE	666	539	726	614
STATISTICAL TESTS				
POLY 3	P=0.177	P=0.352N	P=0.254N	P=0.282
POLY 1.5	P=0.183	P=0.370N	P=0.267N	P=0.286
POLY 6	P=0.174	P=0.331N	P=0.239N	P=0.284
COCH-ARM / FISHERS	P=0.204	P=0.393N	P=0.288N	P=0.312
MAX-ISO-POLY-3	P=0.132	P=0.262N	P=0.178N	P=0.207

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Prostate **Inflammation**				
LESION RATES				
OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	3/43.91	0/44.20	2/46.38	0/42.27
POLY-3 PERCENT (g)	6.8%	0%	4.3%	0%
TERMINAL (d)	2/32 (6%)	0/32 (0%)	1/38 (3%)	0/32 (0%)
FIRST INCIDENCE	714	---	679	---
STATISTICAL TESTS				
POLY 3	P=0.129N	P=0.117N	P=0.475N	P=0.125N
POLY 1.5	P=0.129N	P=0.118N	P=0.485N	P=0.124N
POLY 6	P=0.129N	P=0.116N	P=0.462N	P=0.125N
COCH-ARM / FISHERS	P=0.125N	P=0.121N	P=0.500N	P=0.121N
MAX-ISO-POLY-3	P=0.048N*	P=0.038N*	P=0.306N	P=0.043N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Skin				
Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.85	1/44.54	0/46.18	2/42.32
POLY-3 PERCENT (g)	0%	2.2%	0%	4.7%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	1/32 (3%)
FIRST INCIDENCE	---	633	---	718
STATISTICAL TESTS				
POLY 3	P=0.136	P=0.503	(e)	P=0.229
POLY 1.5	P=0.136	P=0.502	(e)	P=0.230
POLY 6	P=0.137	P=0.505	(e)	P=0.229
COCH-ARM / FISHERS	P=0.140	P=0.500	(e)	P=0.247
MAX-ISO-POLY-3	P=0.077	P=0.162	(e)	P=0.076

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Skin				
Ulcer				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	2/43.94	1/44.20	1/46.53	2/42.56
POLY-3 PERCENT (g)	4.6%	2.3%	2.2%	4.7%
TERMINAL (d)	1/32 (3%)	1/32 (3%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	708	730 (T)	632	666
STATISTICAL TESTS				
POLY 3	P=0.547	P=0.498N	P=0.480N	P=0.683
POLY 1.5	P=0.547	P=0.499N	P=0.488N	P=0.684
POLY 6	P=0.549	P=0.497N	P=0.470N	P=0.685
COCH-ARM / FISHERS	P=0.556	P=0.500N	P=0.500N	P=0.691N
MAX-ISO-POLY-3	P=0.530	P=0.279N	P=0.269N	P=0.487

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Skin: Subcutaneous Tissue Fibrosis				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Spleen				
Hematopoietic Cell Proliferation				
LESION RATES				
OVERALL (a)	2/50 (4%)	5/50 (10%)	7/50 (14%)	6/50 (12%)
POLY-3 RATE (b)	2/43.85	5/45.35	7/46.98	6/44.46
POLY-3 PERCENT (g)	4.6%	11%	14.9%	13.5%
TERMINAL (d)	2/32 (6%)	3/32 (9%)	4/38 (11%)	1/32 (3%)
FIRST INCIDENCE	730 (T)	269	637	429
STATISTICAL TESTS				
POLY 3	P=0.135	P=0.230	P=0.096	P=0.137
POLY 1.5	P=0.129	P=0.225	P=0.089	P=0.132
POLY 6	P=0.147	P=0.233	P=0.107	P=0.144
COCH-ARM / FISHERS	P=0.132	P=0.218	P=0.080	P=0.134
MAX-ISO-POLY-3	P=0.122	P=0.132	P=0.054	P=0.072

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Spleen				
Hyperplasia Lymphoid				
LESION RATES				
OVERALL (a)	7/50 (14%)	11/50 (22%)	11/50 (22%)	4/50 (8%)
POLY-3 RATE (b)	7/43.99	11/44.52	11/46.84	4/42.52
POLY-3 PERCENT (g)	15.9%	24.7%	23.5%	9.4%
TERMINAL (d)	6/32 (19%)	9/32 (28%)	9/38 (24%)	3/32 (9%)
FIRST INCIDENCE	695	668	632	666
STATISTICAL TESTS				
POLY 3	P=0.177N	P=0.222	P=0.261	P=0.279N
POLY 1.5	P=0.176N	P=0.219	P=0.243	P=0.278N
POLY 6	P=0.173N	P=0.225	P=0.286	P=0.277N
COCH-ARM / FISHERS	P=0.159N	P=0.218	P=0.218	P=0.262N
MAX-ISO-POLY-3	P=0.126N	P=0.152	P=0.190	P=0.186N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Spleen: Lymphoid Follicle Atrophy				
LESION RATES				
OVERALL (a)	5/50 (10%)	7/50 (14%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	5/46.27	7/45.73	1/46.76	4/44.60
POLY-3 PERCENT (g)	10.8%	15.3%	2.1%	9%
TERMINAL (d)	0/32 (0%)	1/32 (3%)	0/38 (0%)	1/32 (3%)
FIRST INCIDENCE	339	539	549	18
STATISTICAL TESTS				
POLY 3	P=0.270N	P=0.371	P=0.099N	P=0.523N
POLY 1.5	P=0.266N	P=0.371	P=0.101N	P=0.515N
POLY 6	P=0.271N	P=0.374	P=0.096N	P=0.528N
COCH-ARM / FISHERS	P=0.260N	P=0.380	P=0.102N	P=0.500N
MAX-ISO-POLY-3	P=0.176N	P=0.263	P=0.044N*	P=0.386N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Stomach, Forestomach				
Inflammation				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/44.25	0/44.20	2/46.38	0/42.27
POLY-3 PERCENT (g)	2.3%	0%	4.3%	0%
TERMINAL (d)	0/32 (0%)	0/32 (0%)	1/38 (3%)	0/32 (0%)
FIRST INCIDENCE	617	---	678	---
STATISTICAL TESTS				
POLY 3	P=0.475N	P=0.500N	P=0.516	P=0.509N
POLY 1.5	P=0.472N	P=0.500N	P=0.510	P=0.507N
POLY 6	P=0.477N	P=0.501N	P=0.525	P=0.510N
COCH-ARM / FISHERS	P=0.461N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.349N	P=0.159N	P=0.298	P=0.170N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Stomach, Forestomach				
Ulcer				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	5/50 (10%)	1/50 (2%)
POLY-3 RATE (b)	2/44.19	1/44.36	5/46.45	1/42.27
POLY-3 PERCENT (g)	4.5%	2.3%	10.8%	2.4%
TERMINAL (d)	1/32 (3%)	0/32 (0%)	3/38 (8%)	1/32 (3%)
FIRST INCIDENCE	637	689	678	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.552N	P=0.499N	P=0.237	P=0.515N
POLY 1.5	P=0.545N	P=0.500N	P=0.229	P=0.512N
POLY 6	P=0.555N	P=0.498N	P=0.247	P=0.517N
COCH-ARM / FISHERS	P=0.523N	P=0.500N	P=0.218	P=0.500N
MAX-ISO-POLY-3	P=0.376N	P=0.280N	P=0.139	P=0.297N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Stomach, Forestomach: Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	5/50 (10%)	4/50 (8%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	5/44.33	4/44.32	3/46.25	2/42.27
POLY-3 PERCENT (g)	11.3%	9%	6.5%	4.7%
TERMINAL (d)	3/32 (9%)	3/32 (9%)	2/38 (5%)	2/32 (6%)
FIRST INCIDENCE	617	700	714	730 (T)
STATISTICAL TESTS				
POLY 3	P=0.163N	P=0.500N	P=0.333N	P=0.235N
POLY 1.5	P=0.161N	P=0.501N	P=0.342N	P=0.231N
POLY 6	P=0.163N	P=0.501N	P=0.322N	P=0.238N
COCH-ARM / FISHERS	P=0.151N	P=0.500N	P=0.357N	P=0.218N
MAX-ISO-POLY-3	P=0.223N	P=0.362N	P=0.217N	P=0.137N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Stomach, Forestomach: Epithelium				
Hyperplasia Focal				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.85	1/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	0%	2.3%	0%	0%
TERMINAL (d)	0/32 (0%)	1/32 (3%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	---	730 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.563N	P=0.502	(e)	(e)
POLY 1.5	P=0.565N	P=0.501	(e)	(e)
POLY 6	P=0.561N	P=0.502	(e)	(e)
COCH-ARM / FISHERS	P=0.567N	P=0.500	(e)	(e)
MAX-ISO-POLY-3	P=0.401N	P=0.161	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Testes				
Mineralization				
LESION RATES				
OVERALL (a)	3/50 (6%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/44.12	0/44.20	0/46.18	0/42.27
POLY-3 PERCENT (g)	6.8%	0%	0%	0%
TERMINAL (d)	1/32 (3%)	0/32 (0%)	0/38 (0%)	0/32 (0%)
FIRST INCIDENCE	696	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.044N*	P=0.118N	P=0.111N	P=0.126N
POLY 1.5	P=0.044N*	P=0.119N	P=0.114N	P=0.125N
POLY 6	P=0.043N*	P=0.118N	P=0.107N	P=0.127N
COCH-ARM / FISHERS	P=0.047N*	P=0.121N	P=0.121N	P=0.121N
MAX-ISO-POLY-3	P=0.012N*	P=0.038N*	P=0.038N*	P=0.044N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Testes: Germinal Epithelium Atrophy				
LESION RATES				
OVERALL (a)	2/50 (4%)	4/50 (8%)	5/50 (10%)	4/50 (8%)
POLY-3 RATE (b)	2/44.19	4/44.40	5/46.18	4/42.32
POLY-3 PERCENT (g)	4.5%	9%	10.8%	9.5%
TERMINAL (d)	1/32 (3%)	3/32 (9%)	5/38 (13%)	3/32 (9%)
FIRST INCIDENCE	637	676	730 (T)	718
STATISTICAL TESTS				
POLY 3	P=0.282	P=0.339	P=0.234	P=0.317
POLY 1.5	P=0.287	P=0.338	P=0.228	P=0.321
POLY 6	P=0.279	P=0.340	P=0.243	P=0.314
COCH-ARM / FISHERS	P=0.309	P=0.339	P=0.218	P=0.339
MAX-ISO-POLY-3	P=0.293	P=0.203	P=0.137	P=0.190

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Thyroid Gland: Follicle Cyst				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.85	0/44.20	2/46.18	0/42.27
POLY-3 PERCENT (g)	2.3%	0%	4.3%	0%
TERMINAL (d)	1/32 (3%)	0/32 (0%)	2/38 (5%)	0/32 (0%)
FIRST INCIDENCE	730 (T)	---	730 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.474N	P=0.498N	P=0.518	P=0.507N
POLY 1.5	P=0.472N	P=0.499N	P=0.511	P=0.506N
POLY 6	P=0.475N	P=0.498N	P=0.527	P=0.507N
COCH-ARM / FISHERS	P=0.461N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.346N	P=0.158N	P=0.300	P=0.168N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Tooth Dysplasia				
LESION RATES				
OVERALL (a)	11/13 (85%)	11/15 (73%)	8/9 (89%)	10/13 (77%)
POLY-3 RATE (b)	11/12.87	11/14.57	8/8.43	10/12.86
POLY-3 PERCENT (g)	85.5%	75.5%	95%	77.8%
TERMINAL (d)	8/9 (89%)	10/12 (83%)	6/6 (100%)	9/11 (82%)
FIRST INCIDENCE	637	668	632	718
STATISTICAL TESTS				
POLY 3	P=0.495N	P=0.430N	P=0.511	P=0.501N
POLY 1.5	P=0.498N	P=0.417N	P=0.563	P=0.501N
POLY 6	P=0.492N	P=0.446N	P=0.452	P=0.502N
COCH-ARM / FISHERS	P=0.500N	P=0.400N	P=0.642	P=0.500N
MAX-ISO-POLY-3	P=0.482N	P=0.262N	P=0.261	P=0.309N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Adrenal Cortex Hyperplasia				
LESION RATES				
OVERALL (a)	8/50 (16%)	1/50 (2%)	3/50 (6%)	6/50 (12%)
POLY-3 RATE (b)	8/47.09	1/43.48	3/43.39	6/42.69
POLY-3 PERCENT (g)	17%	2.3%	6.9%	14.1%
TERMINAL (d)	7/38 (18%)	1/31 (3%)	2/34 (6%)	3/32 (9%)
FIRST INCIDENCE	681	729 (T)	673	418
STATISTICAL TESTS				
POLY 3	P=0.553N	P=0.022N*	P=0.126N	P=0.464N
POLY 1.5	P=0.554N	P=0.019N*	P=0.123N	P=0.446N
POLY 6	P=0.544N	P=0.025N*	P=0.125N	P=0.474N
COCH-ARM / FISHERS	P=0.533N	P=0.015N*	P=0.100N	P=0.387N
MAX-ISO-POLY-3	P=0.126N	P=0.011N*	P=0.079N	P=0.357N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Adrenal Cortex Hypertrophy				
LESION RATES				
OVERALL (a)	39/50 (78%)	40/50 (80%)	39/50 (78%)	39/50 (78%)
POLY-3 RATE (b)	39/47.70	40/46.33	39/46.07	39/46.03
POLY-3 PERCENT (g)	81.8%	86.4%	84.7%	84.7%
TERMINAL (d)	35/38 (92%)	30/31 (97%)	29/34 (85%)	29/32 (91%)
FIRST INCIDENCE	578	550	444	225
STATISTICAL TESTS				
POLY 3	P=0.445	P=0.362	P=0.459	P=0.454
POLY 1.5	P=0.442	P=0.412	P=0.421	P=0.468
POLY 6	P=0.509	P=0.323	P=0.564	P=0.491
COCH-ARM / FISHERS	P=0.512N	P=0.500	P=0.595N	P=0.595N
MAX-ISO-POLY-3	P=0.501	P=0.258	P=0.350	P=0.344

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Adrenal Medulla				
Hyperplasia				
LESION RATES				
OVERALL (a)	3/50 (6%)	3/50 (6%)	6/50 (12%)	2/50 (4%)
POLY-3 RATE (b)	3/46.91	3/43.58	6/43.95	2/41.11
POLY-3 PERCENT (g)	6.4%	6.9%	13.7%	4.9%
TERMINAL (d)	3/38 (8%)	2/31 (7%)	5/34 (15%)	1/32 (3%)
FIRST INCIDENCE	729 (T)	704	444	644
STATISTICAL TESTS				
POLY 3	P=0.546N	P=0.628	P=0.211	P=0.560N
POLY 1.5	P=0.527N	P=0.641	P=0.213	P=0.545N
POLY 6	P=0.553N	P=0.612	P=0.212	P=0.568N
COCH-ARM / FISHERS	P=0.463N	P=0.661N	P=0.243	P=0.500N
MAX-ISO-POLY-3	P=0.412N	P=0.463	P=0.132	P=0.385N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Bone Marrow **Hyperplasia**				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/49 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/46.91	0/43.48	1/42.73	2/41.53
POLY-3 PERCENT (g)	0%	0%	2.3%	4.8%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	578	493
STATISTICAL TESTS				
POLY 3	P=0.060	(e)	P=0.481	P=0.211
POLY 1.5	P=0.062	(e)	P=0.482	P=0.217
POLY 6	P=0.060	(e)	P=0.483	P=0.208
COCH-ARM / FISHERS	P=0.070	(e)	P=0.495	P=0.247
MAX-ISO-POLY-3	P=0.078	(e)	P=0.157	P=0.076

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Bone: Femur				
Fibro-osseous Lesion				
LESION RATES				
OVERALL (a)	0/50 (0%)	4/50 (8%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	0/46.91	4/43.52	2/43.18	4/41.60
POLY-3 PERCENT (g)	0%	9.2%	4.6%	9.6%
TERMINAL (d)	0/38 (0%)	3/31 (10%)	2/34 (6%)	3/32 (9%)
FIRST INCIDENCE	---	721	729 (T)	428
STATISTICAL TESTS				
POLY 3	P=0.081	P=0.051	P=0.219	P=0.046*
POLY 1.5	P=0.088	P=0.055	P=0.221	P=0.050*
POLY 6	P=0.077	P=0.047*	P=0.219	P=0.044*
COCH-ARM / FISHERS	P=0.114	P=0.059	P=0.247	P=0.059
MAX-ISO-POLY-3	P=0.049*	P=0.019*	P=0.076	P=0.019*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Brain				
Hydrocephalus				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	2/43.88	1/43.95	0/40.80
POLY-3 PERCENT (g)	0%	4.6%	2.3%	0%
TERMINAL (d)	0/38 (0%)	1/31 (3%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	618	444	---
STATISTICAL TESTS				
POLY 3	P=0.513N	P=0.223	P=0.487	(e)
POLY 1.5	P=0.499N	P=0.228	P=0.488	(e)
POLY 6	P=0.522N	P=0.216	P=0.488	(e)
COCH-ARM / FISHERS	P=0.461N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.351	P=0.076	P=0.158	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Esophagus				
Perforation				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	0/43.48	2/45.18	0/40.80
POLY-3 PERCENT (g)	0%	0%	4.4%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	36	---
STATISTICAL TESTS				
POLY 3	P=0.525	(e)	P=0.229	(e)
POLY 1.5	P=0.544	(e)	P=0.231	(e)
POLY 6	P=0.514	(e)	P=0.229	(e)
COCH-ARM / FISHERS	P=0.595	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.272	(e)	P=0.076	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Esophagus: Periesophageal Tissue Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	0/46.91	0/43.48	3/45.68	1/41.36
POLY-3 PERCENT (g)	0%	0%	6.6%	2.4%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	36	555
STATISTICAL TESTS				
POLY 3	P=0.198	(e)	P=0.114	P=0.475
POLY 1.5	P=0.209	(e)	P=0.115	P=0.481
POLY 6	P=0.194	(e)	P=0.115	P=0.471
COCH-ARM / FISHERS	P=0.247	(e)	P=0.121	P=0.500
MAX-ISO-POLY-3	P=0.135	(e)	P=0.038*	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Eye: Cornea				
Inflammation				
LESION RATES				
OVERALL (a)	2/49 (4%)	1/50 (2%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	2/46.54	1/43.88	3/43.45	0/40.80
POLY-3 PERCENT (g)	4.3%	2.3%	6.9%	0%
TERMINAL (d)	1/38 (3%)	0/31 (0%)	2/34 (6%)	0/32 (0%)
FIRST INCIDENCE	697	618	654	---
STATISTICAL TESTS				
POLY 3	P=0.284N	P=0.520N	P=0.469	P=0.268N
POLY 1.5	P=0.272N	P=0.510N	P=0.474	P=0.258N
POLY 6	P=0.292N	P=0.533N	P=0.468	P=0.276N
COCH-ARM / FISHERS	P=0.237N	P=0.492N	P=0.510	P=0.242N
MAX-ISO-POLY-3	P=0.229N	P=0.304N	P=0.303	P=0.106N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Gallbladder				
Cyst				
LESION RATES				
OVERALL (a)	0/49 (0%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/46.41	2/43.48	1/43.18	1/40.80
POLY-3 PERCENT (g)	0%	4.6%	2.3%	2.5%
TERMINAL (d)	0/38 (0%)	2/31 (7%)	1/34 (3%)	1/32 (3%)
FIRST INCIDENCE	---	729 (T)	729 (T)	729 (T)
STATISTICAL TESTS				
POLY 3	P=0.435	P=0.223	P=0.486	P=0.474
POLY 1.5	P=0.454	P=0.230	P=0.488	P=0.483
POLY 6	P=0.421	P=0.214	P=0.485	P=0.469
COCH-ARM / FISHERS	P=0.505	P=0.253	P=0.505	P=0.505
MAX-ISO-POLY-3	P=0.293	P=0.077	P=0.160	P=0.160

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Gallbladder **Inflammation**				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.41	0/43.48	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Harderian Gland				
Hyperplasia				
LESION RATES				
OVERALL (a)	2/49 (4%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/46.41	1/43.61	1/43.18	0/40.80
POLY-3 PERCENT (g)	4.3%	2.3%	2.3%	0%
TERMINAL (d)	2/38 (5%)	0/31 (0%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	729 (T)	697	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.168N	P=0.522N	P=0.525N	P=0.267N
POLY 1.5	P=0.164N	P=0.510N	P=0.520N	P=0.257N
POLY 6	P=0.169N	P=0.535N	P=0.527N	P=0.274N
COCH-ARM / FISHERS	P=0.150N	P=0.492N	P=0.492N	P=0.242N
MAX-ISO-POLY-3	P=0.168N	P=0.305N	P=0.309N	P=0.105N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Heart				
Cardiomyopathy				
LESION RATES				
OVERALL (a)	35/50 (70%)	40/50 (80%)	38/50 (76%)	31/50 (62%)
POLY-3 RATE (b)	35/49.02	40/46.70	38/45.71	31/44.21
POLY-3 PERCENT (g)	71.4%	85.7%	83.1%	70.1%
TERMINAL (d)	29/38 (76%)	27/31 (87%)	28/34 (82%)	22/32 (69%)
FIRST INCIDENCE	536	550	444	418
STATISTICAL TESTS				
POLY 3	P=0.366N	P=0.066	P=0.128	P=0.537N
POLY 1.5	P=0.301N	P=0.098	P=0.144	P=0.469N
POLY 6	P=0.385N	P=0.045*	P=0.126	P=0.567N
COCH-ARM / FISHERS	P=0.121N	P=0.178	P=0.326	P=0.263N
MAX-ISO-POLY-3	P=0.212N	P=0.042*	P=0.090	P=0.447N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Heart				
Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	0/46.91	2/43.71	3/44.68	1/41.11
POLY-3 PERCENT (g)	0%	4.6%	6.7%	2.4%
TERMINAL (d)	0/38 (0%)	1/31 (3%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	---	668	37	644
STATISTICAL TESTS				
POLY 3	P=0.365	P=0.222	P=0.110	P=0.474
POLY 1.5	P=0.385	P=0.228	P=0.111	P=0.480
POLY 6	P=0.355	P=0.215	P=0.111	P=0.470
COCH-ARM / FISHERS	P=0.444	P=0.247	P=0.121	P=0.500
MAX-ISO-POLY-3	P=0.209	P=0.076	P=0.038*	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Heart				
Mineralization				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	2/43.71	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	4.6%	0%	0%
TERMINAL (d)	0/38 (0%)	1/31 (3%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	668	---	---
STATISTICAL TESTS				
POLY 3	P=0.442N	P=0.222	(e)	(e)
POLY 1.5	P=0.432N	P=0.228	(e)	(e)
POLY 6	P=0.449N	P=0.215	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.292N	P=0.076	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Heart: Artery				
Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/46.91	0/43.48	0/43.18	2/40.80
POLY-3 PERCENT (g)	0%	0%	0%	4.9%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	2/32 (6%)
FIRST INCIDENCE	---	---	---	729 (T)
STATISTICAL TESTS				
POLY 3	P=0.041*	(e)	(e)	P=0.208
POLY 1.5	P=0.042*	(e)	(e)	P=0.215
POLY 6	P=0.041*	(e)	(e)	P=0.203
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.032*	(e)	(e)	P=0.075

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Heart: Valve				
Thrombosis				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	2/43.48	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	4.6%	0%	0%
TERMINAL (d)	0/38 (0%)	2/31 (7%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.443N	P=0.221	(e)	(e)
POLY 1.5	P=0.432N	P=0.227	(e)	(e)
POLY 6	P=0.450N	P=0.213	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.291N	P=0.076	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Intestine Small, Jejunum: Peyer's Patch Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	0/43.48	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Islets, Pancreatic **Hyperplasia**				
LESION RATES				
OVERALL (a)	16/50 (32%)	15/50 (30%)	17/50 (34%)	15/50 (30%)
POLY-3 RATE (b)	16/47.89	15/45.76	17/46.95	15/42.38
POLY-3 PERCENT (g)	33.4%	32.8%	36.2%	35.4%
TERMINAL (d)	12/38 (32%)	9/31 (29%)	10/34 (29%)	10/32 (31%)
FIRST INCIDENCE	596	449	299	555
STATISTICAL TESTS				
POLY 3	P=0.431	P=0.561N	P=0.472	P=0.510
POLY 1.5	P=0.463	P=0.537N	P=0.461	P=0.548
POLY 6	P=0.424	P=0.583	P=0.487	P=0.492
COCH-ARM / FISHERS	P=0.490N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.623	P=0.474N	P=0.387	P=0.424

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Cyst				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	1/43.48	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	2.3%	0%	0%
TERMINAL (d)	0/38 (0%)	1/31 (3%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.586N	P=0.485	(e)	(e)
POLY 1.5	P=0.581N	P=0.491	(e)	(e)
POLY 6	P=0.589N	P=0.478	(e)	(e)
COCH-ARM / FISHERS	P=0.567N	P=0.500	(e)	(e)
MAX-ISO-POLY-3	P=0.421N	P=0.158	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Hydronephrosis				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	0/43.48	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Infarct				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	6/50 (12%)
POLY-3 RATE (b)	0/46.91	2/43.48	0/43.18	6/41.52
POLY-3 PERCENT (g)	0%	4.6%	0%	14.5%
TERMINAL (d)	0/38 (0%)	2/31 (7%)	0/34 (0%)	5/32 (16%)
FIRST INCIDENCE	---	729 (T)	---	477
STATISTICAL TESTS				
POLY 3	P=0.002**	P=0.221	(e)	P=0.010**
POLY 1.5	P=0.002**	P=0.227	(e)	P=0.011*
POLY 6	P=0.002**	P=0.213	(e)	P=0.009**
COCH-ARM / FISHERS	P=0.004**	P=0.247	(e)	P=0.013*
MAX-ISO-POLY-3	P<0.001**	P=0.076	(e)	P=0.004**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Inflammation				
LESION RATES				
OVERALL (a)	7/50 (14%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	7/47.51	2/43.60	0/43.18	1/40.88
POLY-3 PERCENT (g)	14.7%	4.6%	0%	2.5%
TERMINAL (d)	6/38 (16%)	1/31 (3%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	536	701	---	709
STATISTICAL TESTS				
POLY 3	P=0.010N**	P=0.101N	P=0.011N*	P=0.050N*
POLY 1.5	P=0.010N**	P=0.092N	P=0.011N*	P=0.044N*
POLY 6	P=0.010N**	P=0.112N	P=0.011N*	P=0.054N
COCH-ARM / FISHERS	P=0.011N*	P=0.080N	P=0.006N**	P=0.030N*
MAX-ISO-POLY-3	P=0.007N**	P=0.059N	P=0.005N**	P=0.029N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Metaplasia Osseous				
LESION RATES				
OVERALL (a)	0/50 (0%)	3/50 (6%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	3/43.48	2/43.18	0/40.80
POLY-3 PERCENT (g)	0%	6.9%	4.6%	0%
TERMINAL (d)	0/38 (0%)	3/31 (10%)	2/34 (6%)	0/32 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.483N	P=0.106	P=0.219	(e)
POLY 1.5	P=0.463N	P=0.111	P=0.221	(e)
POLY 6	P=0.497N	P=0.100	P=0.219	(e)
COCH-ARM / FISHERS	P=0.409N	P=0.121	P=0.247	(e)
MAX-ISO-POLY-3	P=0.243	P=0.038*	P=0.076	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney **Mineralization**				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	1/43.48	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	2.3%	0%	0%
TERMINAL (d)	0/38 (0%)	1/31 (3%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.586N	P=0.485	(e)	(e)
POLY 1.5	P=0.581N	P=0.491	(e)	(e)
POLY 6	P=0.589N	P=0.478	(e)	(e)
COCH-ARM / FISHERS	P=0.567N	P=0.500	(e)	(e)
MAX-ISO-POLY-3	P=0.421N	P=0.158	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney				
Nephropathy				
LESION RATES				
OVERALL (a)	39/50 (78%)	39/50 (78%)	38/50 (76%)	33/50 (66%)
POLY-3 RATE (b)	39/47.79	39/47.21	38/46.07	33/42.83
POLY-3 PERCENT (g)	81.6%	82.6%	82.5%	77.1%
TERMINAL (d)	33/38 (87%)	28/31 (90%)	31/34 (91%)	27/32 (84%)
FIRST INCIDENCE	673	449	369	477
STATISTICAL TESTS				
POLY 3	P=0.313N	P=0.559	P=0.566	P=0.386N
POLY 1.5	P=0.244N	P=0.571	P=0.540	P=0.307N
POLY 6	P=0.342N	P=0.544	P=0.615N	P=0.433N
COCH-ARM / FISHERS	P=0.081N	P=0.595N	P=0.500N	P=0.133N
MAX-ISO-POLY-3	P=0.431N	P=0.445	P=0.454	P=0.296N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney: Artery **Inflammation**				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	1/43.52	1/43.18	0/40.80
POLY-3 PERCENT (g)	0%	2.3%	2.3%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	---	721	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.633N	P=0.485	P=0.483	(e)
POLY 1.5	P=0.623N	P=0.491	P=0.485	(e)
POLY 6	P=0.639N	P=0.478	P=0.483	(e)
COCH-ARM / FISHERS	P=0.595N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.420	P=0.158	P=0.158	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Kidney: Renal Tubule Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	0/43.48	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Angiectasis				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	2/47.38	0/43.48	2/43.18	0/40.80
POLY-3 PERCENT (g)	4.2%	0%	4.6%	0%
TERMINAL (d)	1/38 (3%)	0/31 (0%)	2/34 (6%)	0/32 (0%)
FIRST INCIDENCE	590	---	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.271N	P=0.257N	P=0.660	P=0.272N
POLY 1.5	P=0.266N	P=0.249N	P=0.665	P=0.262N
POLY 6	P=0.272N	P=0.267N	P=0.658	P=0.280N
COCH-ARM / FISHERS	P=0.247N	P=0.247N	P=0.691N	P=0.247N
MAX-ISO-POLY-3	P=0.173N	P=0.095N	P=0.463	P=0.109N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Basophilic Focus				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/46.91	0/43.48	0/43.18	2/41.00
POLY-3 PERCENT (g)	2.1%	0%	0%	4.9%
TERMINAL (d)	1/38 (3%)	0/31 (0%)	0/34 (0%)	1/32 (3%)
FIRST INCIDENCE	729 (T)	---	---	677
STATISTICAL TESTS				
POLY 3	P=0.235	P=0.515N	P=0.517N	P=0.453
POLY 1.5	P=0.236	P=0.509N	P=0.515N	P=0.465
POLY 6	P=0.237	P=0.522N	P=0.516N	P=0.446
COCH-ARM / FISHERS	P=0.246	P=0.500N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.128	P=0.177N	P=0.179N	P=0.256

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Clear Cell Focus				
LESION RATES				
OVERALL (a)	4/50 (8%)	3/50 (6%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	4/46.91	3/43.83	2/43.18	2/41.77
POLY-3 PERCENT (g)	8.5%	6.8%	4.6%	4.8%
TERMINAL (d)	4/38 (11%)	2/31 (7%)	2/34 (6%)	1/32 (3%)
FIRST INCIDENCE	729 (T)	633	729 (T)	225
STATISTICAL TESTS				
POLY 3	P=0.284N	P=0.537N	P=0.376N	P=0.392N
POLY 1.5	P=0.276N	P=0.523N	P=0.372N	P=0.377N
POLY 6	P=0.288N	P=0.553N	P=0.376N	P=0.403N
COCH-ARM / FISHERS	P=0.248N	P=0.500N	P=0.339N	P=0.339N
MAX-ISO-POLY-3	P=0.392N	P=0.385N	P=0.241N	P=0.256N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Eosinophilic Focus				
LESION RATES				
OVERALL (a)	15/50 (30%)	14/50 (28%)	3/50 (6%)	9/50 (18%)
POLY-3 RATE (b)	15/47.10	14/44.42	3/43.18	9/41.56
POLY-3 PERCENT (g)	31.9%	31.5%	7%	21.7%
TERMINAL (d)	13/38 (34%)	9/31 (29%)	3/34 (9%)	6/32 (19%)
FIRST INCIDENCE	697	618	729 (T)	625
STATISTICAL TESTS				
POLY 3	P=0.060N	P=0.576N	P=0.003N**	P=0.201N
POLY 1.5	P=0.055N	P=0.547N	P=0.002N**	P=0.179N
POLY 6	P=0.060N	P=0.573	P=0.002N**	P=0.211N
COCH-ARM / FISHERS	P=0.040N*	P=0.500N	P=0.002N**	P=0.121N
MAX-ISO-POLY-3	P=0.044N*	P=0.486N	P=0.002N**	P=0.155N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver Inflammation				
LESION RATES				
OVERALL (a)	14/50 (28%)	11/50 (22%)	10/50 (20%)	14/50 (28%)
POLY-3 RATE (b)	14/47.84	11/44.40	10/43.45	14/43.08
POLY-3 PERCENT (g)	29.3%	24.8%	23%	32.5%
TERMINAL (d)	10/38 (26%)	9/31 (29%)	9/34 (27%)	8/32 (25%)
FIRST INCIDENCE	590	550	654	428
STATISTICAL TESTS				
POLY 3	P=0.387	P=0.402N	P=0.331N	P=0.458
POLY 1.5	P=0.404	P=0.369N	P=0.316N	P=0.487
POLY 6	P=0.387	P=0.444N	P=0.340N	P=0.446
COCH-ARM / FISHERS	P=0.489	P=0.322N	P=0.241N	P=0.588N
MAX-ISO-POLY-3	P=0.398	P=0.320N	P=0.260N	P=0.375

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Mixed Cell Focus				
LESION RATES				
OVERALL (a)	2/50 (4%)	5/50 (10%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/46.95	5/43.84	2/43.95	2/41.37
POLY-3 PERCENT (g)	4.3%	11.4%	4.6%	4.8%
TERMINAL (d)	1/38 (3%)	3/31 (10%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	719	668	444	625
STATISTICAL TESTS				
POLY 3	P=0.462N	P=0.189	P=0.670	P=0.647
POLY 1.5	P=0.448N	P=0.200	P=0.671	P=0.659
POLY 6	P=0.468N	P=0.178	P=0.672	P=0.642
COCH-ARM / FISHERS	P=0.397N	P=0.218	P=0.691N	P=0.691N
MAX-ISO-POLY-3	P=0.467N	P=0.108	P=0.473	P=0.450

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver				
Tension Lipidosis				
LESION RATES				
OVERALL (a)	2/50 (4%)	5/50 (10%)	4/50 (8%)	8/50 (16%)
POLY-3 RATE (b)	2/46.91	5/44.62	4/44.17	8/42.33
POLY-3 PERCENT (g)	4.3%	11.2%	9.1%	18.9%
TERMINAL (d)	2/38 (5%)	3/31 (10%)	1/34 (3%)	6/32 (19%)
FIRST INCIDENCE	729 (T)	508	521	232
STATISTICAL TESTS				
POLY 3	P=0.026*	P=0.196	P=0.310	P=0.030*
POLY 1.5	P=0.029*	P=0.204	P=0.310	P=0.034*
POLY 6	P=0.025*	P=0.187	P=0.315	P=0.028*
COCH-ARM / FISHERS	P=0.040*	P=0.218	P=0.339	P=0.046*
MAX-ISO-POLY-3	P=0.024*	P=0.111	P=0.187	P=0.017*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver: Hepatocyte Necrosis				
LESION RATES				
OVERALL (a)	4/50 (8%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	4/46.95	2/44.41	0/43.18	1/40.88
POLY-3 PERCENT (g)	8.5%	4.5%	0%	2.5%
TERMINAL (d)	3/38 (8%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	719	428	---	709
STATISTICAL TESTS				
POLY 3	P=0.094N	P=0.363N	P=0.072N	P=0.224N
POLY 1.5	P=0.093N	P=0.353N	P=0.070N	P=0.211N
POLY 6	P=0.093N	P=0.377N	P=0.072N	P=0.232N
COCH-ARM / FISHERS	P=0.086N	P=0.339N	P=0.059N	P=0.181N
MAX-ISO-POLY-3	P=0.079N	P=0.227N	P=0.028N*	P=0.127N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Liver: Hepatocyte				
Vacuolization Cytoplasmic Diffuse				
LESION RATES				
OVERALL (a)	8/50 (16%)	10/50 (20%)	10/50 (20%)	5/50 (10%)
POLY-3 RATE (b)	8/48.41	10/45.03	10/44.85	5/41.40
POLY-3 PERCENT (g)	16.5%	22.2%	22.3%	12.1%
TERMINAL (d)	4/38 (11%)	4/31 (13%)	5/34 (15%)	3/32 (9%)
FIRST INCIDENCE	536	588	521	625
STATISTICAL TESTS				
POLY 3	P=0.314N	P=0.333	P=0.330	P=0.385N
POLY 1.5	P=0.279N	P=0.357	P=0.336	P=0.353N
POLY 6	P=0.337N	P=0.309	P=0.332	P=0.408N
COCH-ARM / FISHERS	P=0.192N	P=0.398	P=0.398	P=0.277N
MAX-ISO-POLY-3	P=0.288N	P=0.252	P=0.250	P=0.292N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung				
Congestion				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	0/46.91	0/43.48	0/43.18	3/43.54
POLY-3 PERCENT (g)	0%	0%	0%	6.9%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	225
STATISTICAL TESTS				
POLY 3	P=0.010**	(e)	(e)	P=0.106
POLY 1.5	P=0.010**	(e)	(e)	P=0.110
POLY 6	P=0.010**	(e)	(e)	P=0.103
COCH-ARM / FISHERS	P=0.012*	(e)	(e)	P=0.121
MAX-ISO-POLY-3	P=0.009**	(e)	(e)	P=0.038*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung				
Hemorrhage				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	1/43.48	1/43.25	0/40.80
POLY-3 PERCENT (g)	0%	2.3%	2.3%	0%
TERMINAL (d)	0/38 (0%)	1/31 (3%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	729 (T)	711	---
STATISTICAL TESTS				
POLY 3	P=0.633N	P=0.485	P=0.484	(e)
POLY 1.5	P=0.623N	P=0.491	P=0.486	(e)
POLY 6	P=0.639N	P=0.478	P=0.484	(e)
COCH-ARM / FISHERS	P=0.595N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.420	P=0.158	P=0.158	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung				
Inflammation				
LESION RATES				
OVERALL (a)	2/50 (4%)	6/50 (12%)	2/50 (4%)	6/50 (12%)
POLY-3 RATE (b)	2/46.91	6/43.99	2/44.18	6/40.80
POLY-3 PERCENT (g)	4.3%	13.6%	4.5%	14.7%
TERMINAL (d)	2/38 (5%)	3/31 (10%)	1/34 (3%)	6/32 (19%)
FIRST INCIDENCE	729 (T)	633	37	729 (T)
STATISTICAL TESTS				
POLY 3	P=0.136	P=0.113	P=0.672	P=0.093
POLY 1.5	P=0.148	P=0.121	P=0.675	P=0.103
POLY 6	P=0.129	P=0.105	P=0.673	P=0.086
COCH-ARM / FISHERS	P=0.189	P=0.134	P=0.691N	P=0.134
MAX-ISO-POLY-3	P=0.087	P=0.062	P=0.475	P=0.055

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung				
Thrombosis				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	0/43.48	2/43.25	0/40.80
POLY-3 PERCENT (g)	0%	0%	4.6%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	---	---	711	---
STATISTICAL TESTS				
POLY 3	P=0.530	(e)	P=0.220	(e)
POLY 1.5	P=0.548	(e)	P=0.222	(e)
POLY 6	P=0.519	(e)	P=0.220	(e)
COCH-ARM / FISHERS	P=0.595	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.263	(e)	P=0.076	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung: Alveolar Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	2/50 (4%)	3/50 (6%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	2/46.91	3/43.48	2/43.23	1/40.80
POLY-3 PERCENT (g)	4.3%	6.9%	4.6%	2.5%
TERMINAL (d)	2/38 (5%)	3/31 (10%)	1/34 (3%)	1/32 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	715	729 (T)
STATISTICAL TESTS				
POLY 3	P=0.368N	P=0.466	P=0.664	P=0.548N
POLY 1.5	P=0.355N	P=0.479	P=0.667	P=0.536N
POLY 6	P=0.375N	P=0.449	P=0.665	P=0.557N
COCH-ARM / FISHERS	P=0.313N	P=0.500	P=0.691N	P=0.500N
MAX-ISO-POLY-3	P=0.421N	P=0.300	P=0.467	P=0.333N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lung: Alveolus				
Infiltration Cellular Histiocyte				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	0/43.48	2/43.27	0/40.80
POLY-3 PERCENT (g)	0%	0%	4.6%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	711	---
STATISTICAL TESTS				
POLY 3	P=0.530	(e)	P=0.220	(e)
POLY 1.5	P=0.548	(e)	P=0.222	(e)
POLY 6	P=0.519	(e)	P=0.220	(e)
COCH-ARM / FISHERS	P=0.595	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.263	(e)	P=0.076	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lymph Node, Mandibular				
Infiltration Cellular Histiocyte				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/49 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	0/42.48	2/43.18	0/40.80
POLY-3 PERCENT (g)	0%	0%	4.6%	0%
TERMINAL (d)	0/38 (0%)	0/30 (0%)	2/34 (6%)	0/32 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.532	(e)	P=0.219	(e)
POLY 1.5	P=0.549	(e)	P=0.221	(e)
POLY 6	P=0.521	(e)	P=0.219	(e)
COCH-ARM / FISHERS	P=0.596	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.263	(e)	P=0.076	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lymph Node, Mesenteric				
Infiltration Cellular Histiocyte				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/45.91	0/43.48	2/43.68	0/40.80
POLY-3 PERCENT (g)	0%	0%	4.6%	0%
TERMINAL (d)	0/37 (0%)	0/31 (0%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	---	---	578	---
STATISTICAL TESTS				
POLY 3	P=0.533	(e)	P=0.226	(e)
POLY 1.5	P=0.551	(e)	P=0.227	(e)
POLY 6	P=0.522	(e)	P=0.228	(e)
COCH-ARM / FISHERS	P=0.598	(e)	P=0.253	(e)
MAX-ISO-POLY-3	P=0.266	(e)	P=0.077	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lymph Node, Mesenteric				
Inflammation				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/45.91	0/43.48	2/43.18	1/41.17
POLY-3 PERCENT (g)	0%	0%	4.6%	2.4%
TERMINAL (d)	0/37 (0%)	0/31 (0%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	---	---	728	625
STATISTICAL TESTS				
POLY 3	P=0.210	(e)	P=0.224	P=0.478
POLY 1.5	P=0.218	(e)	P=0.226	P=0.485
POLY 6	P=0.207	(e)	P=0.224	P=0.475
COCH-ARM / FISHERS	P=0.249	(e)	P=0.253	P=0.505
MAX-ISO-POLY-3	P=0.182	(e)	P=0.077	P=0.160

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Lymph Node: Renal				
Hemorrhage				
LESION RATES				
OVERALL (a)	0/4 (0%)	2/4 (50%)	1/6 (17%)	0/6 (0%)
POLY-3 RATE (b)	0/3.33	2/4.00	1/4.92	0/4.97
POLY-3 PERCENT (g)	0%	50%	20.3%	0%
TERMINAL (d)	0/0 (0%)	0/2 (0%)	0/3 (0%)	0/3 (0%)
FIRST INCIDENCE	---	550	578	---
STATISTICAL TESTS				
POLY 3	P=0.313N	P=0.241	P=0.578	(e)
POLY 1.5	P=0.322N	P=0.218	P=0.563	(e)
POLY 6	P=0.290N	P=0.282	P=0.601	(e)
COCH-ARM / FISHERS	P=0.336N	P=0.214	P=0.600	(e)
MAX-ISO-POLY-3	P=0.274N	P=0.075	P=0.225	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Mammary Gland				
Hyperplasia Focal				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	0/46.91	2/43.48	3/43.95	2/40.80
POLY-3 PERCENT (g)	0%	4.6%	6.8%	4.9%
TERMINAL (d)	0/38 (0%)	2/31 (7%)	2/34 (6%)	2/32 (6%)
FIRST INCIDENCE	---	729 (T)	444	729 (T)
STATISTICAL TESTS				
POLY 3	P=0.179	P=0.221	P=0.107	P=0.208
POLY 1.5	P=0.193	P=0.227	P=0.108	P=0.215
POLY 6	P=0.171	P=0.213	P=0.108	P=0.203
COCH-ARM / FISHERS	P=0.237	P=0.247	P=0.121	P=0.247
MAX-ISO-POLY-3	P=0.150	P=0.076	P=0.038*	P=0.075

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Mesentery				
Necrosis				
LESION RATES				
OVERALL (a)	8/8 (100%)	8/9 (89%)	5/7 (71%)	4/4 (100%)
POLY-3 RATE (b)	8/8.00	8/8.23	5/6.50	4/4.00
POLY-3 PERCENT (g)	100%	97.2%	76.9%	100%
TERMINAL (d)	7/7 (100%)	7/7 (100%)	5/6 (83%)	2/2 (100%)
FIRST INCIDENCE	712	704	729 (T)	644
STATISTICAL TESTS				
POLY 3	P=0.574N	P=0.999N	P=0.267N	(e)
POLY 1.5	P=0.550N	P=0.856N	P=0.225N	(e)
POLY 6	P=0.613N	P=1.000N	P=0.343N	(e)
COCH-ARM / FISHERS	P=0.534N	P=0.529N	P=0.200N	(e)
MAX-ISO-POLY-3	P=0.264N	P=0.178N	P=0.070N	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Nose				
Inflammation				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	4/50 (8%)	3/49 (6%)
POLY-3 RATE (b)	1/46.95	0/43.48	4/45.54	3/41.86
POLY-3 PERCENT (g)	2.1%	0%	8.8%	7.2%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	1/32 (3%)
FIRST INCIDENCE	719	---	369	232
STATISTICAL TESTS				
POLY 3	P=0.088	P=0.515N	P=0.170	P=0.265
POLY 1.5	P=0.092	P=0.509N	P=0.167	P=0.274
POLY 6	P=0.088	P=0.523N	P=0.175	P=0.261
COCH-ARM / FISHERS	P=0.106	P=0.500N	P=0.181	P=0.301
MAX-ISO-POLY-3	P=0.105	P=0.177N	P=0.081	P=0.139

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Nose				
Polyp, Inflammatory				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/46.91	0/43.48	0/43.18	0/40.61
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Ovary				
Cyst				
LESION RATES				
OVERALL (a)	4/50 (8%)	7/50 (14%)	6/50 (12%)	2/50 (4%)
POLY-3 RATE (b)	4/46.91	7/43.93	6/43.18	2/40.88
POLY-3 PERCENT (g)	8.5%	15.9%	13.9%	4.9%
TERMINAL (d)	4/38 (11%)	4/31 (13%)	6/34 (18%)	1/32 (3%)
FIRST INCIDENCE	729 (T)	648	729 (T)	709
STATISTICAL TESTS				
POLY 3	P=0.280N	P=0.224	P=0.318	P=0.403N
POLY 1.5	P=0.258N	P=0.238	P=0.325	P=0.385N
POLY 6	P=0.292N	P=0.209	P=0.318	P=0.414N
COCH-ARM / FISHERS	P=0.196N	P=0.262	P=0.370	P=0.339N
MAX-ISO-POLY-3	P=0.219N	P=0.147	P=0.220	P=0.266N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Ovary				
Hemorrhage				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/46.91	1/43.48	2/43.18	1/41.03
POLY-3 PERCENT (g)	0%	2.3%	4.6%	2.4%
TERMINAL (d)	0/38 (0%)	1/31 (3%)	2/34 (6%)	0/32 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	668
STATISTICAL TESTS				
POLY 3	P=0.309	P=0.485	P=0.219	P=0.473
POLY 1.5	P=0.323	P=0.491	P=0.221	P=0.480
POLY 6	P=0.301	P=0.478	P=0.219	P=0.469
COCH-ARM / FISHERS	P=0.366	P=0.500	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.239	P=0.158	P=0.076	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Ovary				
Inflammation				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	2/46.98	0/43.48	2/43.68	0/40.80
POLY-3 PERCENT (g)	4.3%	0%	4.6%	0%
TERMINAL (d)	1/38 (3%)	0/31 (0%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	712	---	578	---
STATISTICAL TESTS				
POLY 3	P=0.269N	P=0.255N	P=0.667	P=0.270N
POLY 1.5	P=0.265N	P=0.248N	P=0.669	P=0.261N
POLY 6	P=0.270N	P=0.264N	P=0.669	P=0.276N
COCH-ARM / FISHERS	P=0.247N	P=0.247N	P=0.691N	P=0.247N
MAX-ISO-POLY-3	P=0.170N	P=0.093N	P=0.470	P=0.107N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pancreas				
Basophilic Focus				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	2/44.06	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	4.5%	0%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	588	---	---
STATISTICAL TESTS				
POLY 3	P=0.441N	P=0.223	(e)	(e)
POLY 1.5	P=0.432N	P=0.229	(e)	(e)
POLY 6	P=0.448N	P=0.218	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.294N	P=0.076	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pancreas				
Infiltration Cellular				
LESION RATES				
OVERALL (a)	0/50 (0%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	3/43.48	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	6.9%	0%	0%
TERMINAL (d)	0/38 (0%)	3/31 (10%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.357N	P=0.106	(e)	(e)
POLY 1.5	P=0.344N	P=0.111	(e)	(e)
POLY 6	P=0.367N	P=0.100	(e)	(e)
COCH-ARM / FISHERS	P=0.311N	P=0.121	(e)	(e)
MAX-ISO-POLY-3	P=0.207N	P=0.038*	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pancreas				
Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	2/43.61	0/43.18	0/40.80
POLY-3 PERCENT (g)	0%	4.6%	0%	0%
TERMINAL (d)	0/38 (0%)	1/31 (3%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	697	---	---
STATISTICAL TESTS				
POLY 3	P=0.442N	P=0.221	(e)	(e)
POLY 1.5	P=0.432N	P=0.228	(e)	(e)
POLY 6	P=0.450N	P=0.214	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.292N	P=0.076	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pancreas: Acinus **Hyperplasia**				
LESION RATES				
OVERALL (a)	4/50 (8%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	4/46.91	1/43.48	1/43.18	0/40.80
POLY-3 PERCENT (g)	8.5%	2.3%	2.3%	0%
TERMINAL (d)	4/38 (11%)	1/31 (3%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.037N*	P=0.203N	P=0.205N	P=0.080N
POLY 1.5	P=0.037N*	P=0.193N	P=0.202N	P=0.075N
POLY 6	P=0.037N*	P=0.214N	P=0.205N	P=0.084N
COCH-ARM / FISHERS	P=0.034N*	P=0.181N	P=0.181N	P=0.059N
MAX-ISO-POLY-3	P=0.030N*	P=0.106N	P=0.108N	P=0.036N*

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pituitary Gland: Pars Distalis				
Cyst				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/46.91	2/43.48	0/43.18	0/39.80
POLY-3 PERCENT (g)	0%	4.6%	0%	0%
TERMINAL (d)	0/38 (0%)	2/31 (7%)	0/34 (0%)	0/31 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.447N	P=0.221	(e)	(e)
POLY 1.5	P=0.437N	P=0.227	(e)	(e)
POLY 6	P=0.455N	P=0.213	(e)	(e)
COCH-ARM / FISHERS	P=0.409N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.298N	P=0.076	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Pituitary Gland: Pars Distalis				
Hyperplasia				
LESION RATES				
OVERALL (a)	18/50 (36%)	18/50 (36%)	19/50 (38%)	18/49 (37%)
POLY-3 RATE (b)	18/46.95	18/44.60	19/43.18	18/39.96
POLY-3 PERCENT (g)	38.3%	40.4%	44%	45%
TERMINAL (d)	17/38 (45%)	14/31 (45%)	19/34 (56%)	16/31 (52%)
FIRST INCIDENCE	719	633	729 (T)	709
STATISTICAL TESTS				
POLY 3	P=0.277	P=0.506	P=0.370	P=0.339
POLY 1.5	P=0.329	P=0.534	P=0.386	P=0.396
POLY 6	P=0.248	P=0.481	P=0.366	P=0.303
COCH-ARM / FISHERS	P=0.497	P=0.582N	P=0.500	P=0.553
MAX-ISO-POLY-3	P=0.446	P=0.421	P=0.299	P=0.277

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Skin				
Inflammation				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/46.91	0/43.48	1/43.68	0/40.80
POLY-3 PERCENT (g)	2.1%	0%	2.3%	0%
TERMINAL (d)	1/38 (3%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	729 (T)	---	578	---
STATISTICAL TESTS				
POLY 3	P=0.418N	P=0.515N	P=0.744	P=0.528N
POLY 1.5	P=0.417N	P=0.509N	P=0.745	P=0.520N
POLY 6	P=0.417N	P=0.522N	P=0.746	P=0.533N
COCH-ARM / FISHERS	P=0.405N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.310N	P=0.177N	P=0.479	P=0.192N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Skin				
Ulcer				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/47.05	1/43.50	0/43.18	0/40.80
POLY-3 PERCENT (g)	2.1%	2.3%	0%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	692	725	---	---
STATISTICAL TESTS				
POLY 3	P=0.246N	P=0.743	P=0.517N	P=0.528N
POLY 1.5	P=0.245N	P=0.750	P=0.515N	P=0.521N
POLY 6	P=0.247N	P=0.734	P=0.518N	P=0.534N
COCH-ARM / FISHERS	P=0.236N	P=0.753N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.296N	P=0.477	P=0.180N	P=0.193N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Skin: Subcutaneous Tissue Fibrosis				
LESION RATES				
OVERALL (a)	2/50 (4%)	4/50 (8%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/46.91	4/43.50	1/43.18	1/40.80
POLY-3 PERCENT (g)	4.3%	9.2%	2.3%	2.5%
TERMINAL (d)	2/38 (5%)	3/31 (10%)	1/34 (3%)	1/32 (3%)
FIRST INCIDENCE	729 (T)	725	729 (T)	729 (T)
STATISTICAL TESTS				
POLY 3	P=0.279N	P=0.303	P=0.529N	P=0.548N
POLY 1.5	P=0.268N	P=0.317	P=0.525N	P=0.536N
POLY 6	P=0.286N	P=0.287	P=0.529N	P=0.557N
COCH-ARM / FISHERS	P=0.232N	P=0.339	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.302N	P=0.183	P=0.312N	P=0.333N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Spleen				
Hematopoietic Cell Proliferation				
LESION RATES				
OVERALL (a)	4/50 (8%)	2/50 (4%)	2/49 (4%)	2/50 (4%)
POLY-3 RATE (b)	4/47.45	2/43.78	2/42.52	2/40.88
POLY-3 PERCENT (g)	8.4%	4.6%	4.7%	4.9%
TERMINAL (d)	2/38 (5%)	1/31 (3%)	0/34 (0%)	1/32 (3%)
FIRST INCIDENCE	590	648	673	709
STATISTICAL TESTS				
POLY 3	P=0.335N	P=0.375N	P=0.389N	P=0.408N
POLY 1.5	P=0.326N	P=0.360N	P=0.384N	P=0.388N
POLY 6	P=0.338N	P=0.393N	P=0.389N	P=0.423N
COCH-ARM / FISHERS	P=0.293N	P=0.339N	P=0.349N	P=0.339N
MAX-ISO-POLY-3	P=0.394N	P=0.239N	P=0.252N	P=0.272N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Spleen				
Hyperplasia Lymphoid				
LESION RATES				
OVERALL (a)	22/50 (44%)	23/50 (46%)	24/49 (49%)	12/50 (24%)
POLY-3 RATE (b)	22/47.45	23/44.45	24/43.58	12/41.16
POLY-3 PERCENT (g)	46.4%	51.7%	55.1%	29.2%
TERMINAL (d)	20/38 (53%)	17/31 (55%)	21/34 (62%)	10/32 (31%)
FIRST INCIDENCE	590	633	299	654
STATISTICAL TESTS				
POLY 3	P=0.058N	P=0.378	P=0.266	P=0.072N
POLY 1.5	P=0.044N*	P=0.425	P=0.278	P=0.056N
POLY 6	P=0.065N	P=0.332	P=0.268	P=0.082N
COCH-ARM / FISHERS	P=0.018N*	P=0.500	P=0.384	P=0.028N*
MAX-ISO-POLY-3	P=0.038N*	P=0.307	P=0.210	P=0.057N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Spleen: Lymphoid Follicle Atrophy				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	4/49 (8%)	3/50 (6%)
POLY-3 RATE (b)	2/48.01	1/43.96	4/44.37	3/42.80
POLY-3 PERCENT (g)	4.2%	2.3%	9%	7%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	536	588	37	410
STATISTICAL TESTS				
POLY 3	P=0.249	P=0.531N	P=0.302	P=0.448
POLY 1.5	P=0.257	P=0.519N	P=0.305	P=0.461
POLY 6	P=0.245	P=0.545N	P=0.302	P=0.439
COCH-ARM / FISHERS	P=0.291	P=0.500N	P=0.329	P=0.500
MAX-ISO-POLY-3	P=0.282	P=0.314N	P=0.182	P=0.290

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Stomach, Forestomach				
Inflammation				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	1/43.60	1/43.23	0/40.80
POLY-3 PERCENT (g)	0%	2.3%	2.3%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	701	715	---
STATISTICAL TESTS				
POLY 3	P=0.633N	P=0.485	P=0.484	(e)
POLY 1.5	P=0.623N	P=0.491	P=0.486	(e)
POLY 6	P=0.639N	P=0.479	P=0.484	(e)
COCH-ARM / FISHERS	P=0.595N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.420	P=0.158	P=0.158	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Stomach, Forestomach				
Ulcer				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	0/43.48	1/43.26	0/40.80
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	0/34 (0%)	0/32 (0%)
FIRST INCIDENCE	---	---	709	---
STATISTICAL TESTS				
POLY 3	P=0.644	(e)	P=0.484	(e)
POLY 1.5	P=0.658	(e)	P=0.486	(e)
POLY 6	P=0.635	(e)	P=0.484	(e)
COCH-ARM / FISHERS	P=0.694	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.397	(e)	P=0.158	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Stomach, Forestomach: Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	2/50 (4%)	2/50 (4%)	3/50 (6%)	4/50 (8%)
POLY-3 RATE (b)	2/46.91	2/43.72	3/43.31	4/40.80
POLY-3 PERCENT (g)	4.3%	4.6%	6.9%	9.8%
TERMINAL (d)	2/38 (5%)	0/31 (0%)	1/34 (3%)	4/32 (13%)
FIRST INCIDENCE	729 (T)	697	709	729 (T)
STATISTICAL TESTS				
POLY 3	P=0.170	P=0.668	P=0.464	P=0.275
POLY 1.5	P=0.181	P=0.678	P=0.467	P=0.292
POLY 6	P=0.165	P=0.657	P=0.465	P=0.265
COCH-ARM / FISHERS	P=0.216	P=0.691N	P=0.500	P=0.339
MAX-ISO-POLY-3	P=0.259	P=0.471	P=0.299	P=0.171

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Stomach, Forestomach: Epithelium Hyperplasia Focal				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/46.91	1/44.15	2/43.45	0/40.80
POLY-3 PERCENT (g)	0%	2.3%	4.6%	0%
TERMINAL (d)	0/38 (0%)	0/31 (0%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	---	508	654	---
STATISTICAL TESTS				
POLY 3	P=0.619	P=0.488	P=0.221	(e)
POLY 1.5	P=0.638	P=0.493	P=0.222	(e)
POLY 6	P=0.605	P=0.482	P=0.222	(e)
COCH-ARM / FISHERS	P=0.616N	P=0.500	P=0.247	(e)
MAX-ISO-POLY-3	P=0.344	P=0.158	P=0.076	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Thyroid Gland: Follicle Cyst				
LESION RATES				
OVERALL (a)	0/49 (0%)	1/50 (2%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/46.00	1/43.48	2/43.18	1/40.80
POLY-3 PERCENT (g)	0%	2.3%	4.6%	2.5%
TERMINAL (d)	0/38 (0%)	1/31 (3%)	2/34 (6%)	1/32 (3%)
FIRST INCIDENCE	---	729 (T)	729 (T)	729 (T)
STATISTICAL TESTS				
POLY 3	P=0.310	P=0.489	P=0.223	P=0.476
POLY 1.5	P=0.326	P=0.495	P=0.226	P=0.484
POLY 6	P=0.300	P=0.481	P=0.223	P=0.471
COCH-ARM / FISHERS	P=0.371	P=0.505	P=0.253	P=0.505
MAX-ISO-POLY-3	P=0.242	P=0.160	P=0.077	P=0.160

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Tooth				
Dysplasia				
LESION RATES				
OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Uterus				
Inflammation				
LESION RATES				
OVERALL (a)	2/50 (4%)	2/50 (4%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	2/46.98	2/43.61	2/43.18	0/40.80
POLY-3 PERCENT (g)	4.3%	4.6%	4.6%	0%
TERMINAL (d)	1/38 (3%)	1/31 (3%)	1/34 (3%)	0/32 (0%)
FIRST INCIDENCE	712	697	728	---
STATISTICAL TESTS				
POLY 3	P=0.199N	P=0.667	P=0.663	P=0.270N
POLY 1.5	P=0.190N	P=0.677	P=0.667	P=0.261N
POLY 6	P=0.204N	P=0.654	P=0.663	P=0.276N
COCH-ARM / FISHERS	P=0.163N	P=0.691N	P=0.691N	P=0.247N
MAX-ISO-POLY-3	P=0.229N	P=0.470	P=0.466	P=0.107N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	0 MG/KG	1250 MG/KG	2500 MG/KG	5000 MG/KG
Uterus: Endometrium				
Hyperplasia Cystic				
LESION RATES				
OVERALL (a)	47/50 (94%)	40/50 (80%)	35/50 (70%)	43/50 (86%)
POLY-3 RATE (b)	47/48.44	40/48.23	35/46.24	43/46.40
POLY-3 PERCENT (g)	97%	82.9%	75.7%	92.7%
TERMINAL (d)	38/38 (100%)	27/31 (87%)	26/34 (77%)	30/32 (94%)
FIRST INCIDENCE	590	449	299	225
STATISTICAL TESTS				
POLY 3	P=0.395N	P=0.015N*	P<0.001N**	P=0.278N
POLY 1.5	P=0.359N	P=0.022N*	P=0.002N**	P=0.250N
POLY 6	P=0.395N	P=0.010N**	P<0.001N**	P=0.254N
COCH-ARM / FISHERS	P=0.235N	P=0.036N*	P=0.002N**	P=0.159N
MAX-ISO-POLY-3	P=0.030N*	P=0.006N**	P<0.001N**	P=0.132N

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(e)	Value of Statistic cannot be computed.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
(g)	Poly-3 adjusted lifetime tumor incidence.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
N	Indicates a negative trend for all tests
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***